| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SP-C |
| Uniprot No | P11686 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-58aa |
| 氨基酸序列 | FGIPCCPVHLKRLLIVVVVVVLIVVVIVGALLMGL |
| 预测分子量 | 5.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组SP-C蛋白的3篇代表性文献摘要：
1. **《Expression and characterization of a human surfactant protein C with a poly-histidine tag》**
- 作者：Curstedt T, et al.
- 摘要：研究通过大肠杆菌系统表达带组氨酸标签的重组人SP-C蛋白，优化纯化流程并验证其α螺旋结构与天然蛋白相似性，证明其具备表面活性功能。
2. **《Structural analysis of recombinant pulmonary surfactant protein C》**
- 作者：Johansson J, et al.
- 摘要：利用核磁共振技术解析重组SP-C蛋白的膜结合结构域三维构象，揭示其两亲性α螺旋结构对维持肺泡表面张力的关键作用机制。
3. **《Recombinant surfactant protein C-based surfactant for acute respiratory distress syndrome》**
- 作者：Spragg RG, et al.
- 摘要：临床试验评估含重组SP-C的合成表面活性剂在ARDS治疗中的效果，证实其能显著改善患者氧合指数并降低死亡率，展示临床应用潜力。
(注：上述文献为示例性内容，实际研究请通过PubMed或Web of Science检索最新文献)
**Background of SP-C Recombinant Protein**
Surfactant Protein C (SP-C) is a critical component of pulmonary surfactant, a lipid-protein complex essential for reducing alveolar surface tension and preventing lung collapse during respiration. Encoded by the *SFTPC* gene, SP-C is a highly hydrophobic, 35-amino acid protein predominantly expressed in alveolar type II cells. Its unique structure, characterized by an α-helical transmembrane domain, enables interaction with surfactant lipids, stabilizing the surfactant layer and maintaining alveolar integrity.
Mutations in *SFTPC* are linked to severe lung disorders, such as neonatal respiratory distress syndrome (NRDS) and interstitial lung diseases (ILDs) in children and adults. These mutations often lead to misfolded SP-C aggregates, triggering endoplasmic reticulum stress, cellular dysfunction, and progressive lung damage. Studying SP-C’s role in these pathologies has driven interest in recombinant SP-C (recSP-C) production for therapeutic and research applications.
Native SP-C isolation from animal or human sources is challenging due to its hydrophobicity, low abundance, and contamination risks. Recombinant DNA technology offers a scalable alternative, utilizing bacterial (e.g., *E. coli*), yeast, or mammalian expression systems. However, recSP-C production faces hurdles, including improper folding, insolubility, and loss of function. Advanced strategies, such as fusion tags, chaperone co-expression, or chemical synthesis of peptide fragments, have improved yield and stability.
Therapeutic recSP-C aims to replace dysfunctional surfactant in respiratory diseases. It is also a tool for studying SP-C biogenesis, mutation-driven pathogenicity, and drug screening. Despite progress, optimizing recSP-C’s structural fidelity and functional equivalence to native SP-C remains a focus, highlighting its potential in advancing pulmonary medicine and molecular research.
×
